The characteristics and risk factors for cisplatin-induced acute kidney injury in the elderly

References

• FuscoSGarastoSCorsonelloAMedication-induced nephrotoxicity in older patientsCurr Drug Metab2016617608625
   Web of Science ®Google Scholar
• SmetanaKJrLacinaLSzaboPDvořánkováBAgeing as an important risk factor for cancerAnticancer Res201636105009501727798859
   PubMed Web of Science ®Google Scholar
• SmithBDSmithGLHurriaAFuture of cancer incidence in the United States: burdens upon an aging, changing nationJ Clin Oncol200927172758276519403886
   PubMed Web of Science ®Google Scholar
• OhmichiMHayakawaJTasakaKKurachiHMurataYMechanisms of platinum drug resistanceTrends Pharmacol Sci200526311311615749154
   PubMed Web of Science ®Google Scholar
• National Institutes of HealthClinical Trials Database Available from: https://www.clinicaltrials.govAccessed May 21, 2018
   Google Scholar
• HaniganMHDevarajanPCisplatin nephrotoxicity: molecular mechanismsCancer Ther20031476118185852
   PubMedGoogle Scholar
• PablaNDongZCisplatin nephrotoxicity: mechanisms and renoprotective strategiesKidney Int2008739994100718272962
   PubMed Web of Science ®Google Scholar
• ManoharSLeungNCisplatin nephrotoxicity: a review of the literatureJ Nephrol2018311152528382507
   PubMed Web of Science ®Google Scholar
• KilbrideHSStevensPEEaglestoneGAccuracy of the MDRD (Modification of Diet in Renal Disease) study and CKD-EPI (CKD Epidemiology Collaboration) equations for estimation of GFR in the elderlyAm J Kidney Dis2013611576622889713
   PubMed Web of Science ®Google Scholar
• MichelsWMGrootendorstDCVerduijnMPerformance of the Cockcroft-Gault, MDRD, and new CKD-EPI formulas in relation to GFR, age, and body sizeClin J Am Soc Nephrol2010561003100920299365
   PubMed Web of Science ®Google Scholar
• LatchaSJaimesEAPatilSLong-term renal outcomes after cisplatin treatmentClin J Am Soc Nephrol20161171173117927073199
   PubMed Web of Science ®Google Scholar
• MizunoTSatoWIshikawaKKDIGO (Kidney Disease: Improving Global Outcomes) criteria could be a useful outcome predictor of cisplatin-induced acute kidney injuryOncology201282635435922722365
   PubMed Web of Science ®Google Scholar
• MáthéCBohácsADuffekLCisplatin nephrotoxicity aggravated by cardiovascular disease and diabetes in lung cancer patientsEur Respir J201137488889420650984
   PubMed Web of Science ®Google Scholar
• NinomiyaKHottaKHisamoto-SatoAShort-term low-volume hydration in cisplatin-based chemotherapy for patients with lung cancer: the second prospective feasibility study in the Okayama Lung Cancer Study Group Trial 1201Int J Clin Oncol2016211818726093520
   PubMed Web of Science ®Google Scholar
• CronaDJFasoANishijimaTFA systematic review of strategies to prevent cisplatin-induced nephrotoxicityOncologist201722560961928438887
   PubMed Web of Science ®Google Scholar
• EspandiariPRosenzweigBZhangJAge-related differences in susceptibility to cisplatin-induced renal toxicityJ Appl Toxicol201030217218219839026
   PubMed Web of Science ®Google Scholar
• WenJZengMShuYAging increases the susceptibility of cisplatin-induced nephrotoxicityAge (Dordr)201537611226534724
   PubMed Web of Science ®Google Scholar
• RosnerMHAcute kidney injury in the elderlyClin Geriatr Med201329356557823849008
   PubMed Web of Science ®Google Scholar
• HrusheskyWJShimpWKennedyBJLack of age-dependent cisplatin nephrotoxicityAm J Med19847645795846538750
   PubMed Web of Science ®Google Scholar
• LavoléADanelSBaudrinLRoutine administration of a single dose of cisplatin ≥75 mg/m2 after short hydration in an outpatient lung-cancer clinicBull Cancer2012994E43E4822450449
   PubMed Web of Science ®Google Scholar
• AlmanricKMarceauNCantinABertinÉRisk factors for nephrotoxicity associated with cisplatinCan J Hosp Pharm20177029910628487576
   PubMed Web of Science ®Google Scholar
• PalmerBFRenal dysfunction complicating the treatment of hypertensionN Engl J Med2002347161256126112393824
   PubMed Web of Science ®Google Scholar
• KurtEManavogluODilekKOrhanBEvrenselTEffect of cisplatin on plasma renin activity and serum aldosterone levelsClin Nephrol199952639739810604651
   PubMed Web of Science ®Google Scholar
• KomakiKKusabaTTanakaMLower blood pressure and risk of cisplatin nephrotoxicity: a retrospective cohort studyBMC Cancer201717114428219368
   PubMed Web of Science ®Google Scholar
• SpiottoMTCaoHMellLTobackFGACE inhibitors predict for acute kidney injury during chemoradiation for head and neck cancerAnticancer Drugs201526334334925486599
   PubMed Web of Science ®Google Scholar
• RadesDSeidlDJanssenSChemoradiation of locally advanced squamous cell carcinoma of the head-and-neck (LASCCHN): is 20 mg/m2 cisplatin on five days every four weeks an alternative to 100 mg/m2 cisplatin every three weeks?Oral Oncol201659677227424184
   PubMed Web of Science ®Google Scholar
• UtkanGBüyükçelikAYalçinBDivided dose of cisplatin combined with gemcitabine in malignant mesotheliomaLung Cancer200653336737416828196
   PubMed Web of Science ®Google Scholar
• EspeliVZuccaEGhielminiMWeekly and 3-weekly cisplatin concurrent with intensity-modulated radiotherapy in locally advanced head and neck squamous cell cancerOral Oncol201248326627122079100
   PubMed Web of Science ®Google Scholar
• SzturzPWoutersKKiyotaNWeekly low-dose versus three-weekly high-dose cisplatin for concurrent chemoradiation in locoregionally advanced non-nasopharyngeal head and neck cancer: a systematic review and meta-analysis of aggregate dataOncologist20172291056106628533474
   PubMed Web of Science ®Google Scholar
• ReecePAStaffordIRussellJKhanMGillPGCreatinine clearance as a predictor of ultrafilterable platinum disposition in cancer patients treated with cisplatin: relationship between peak ultrafilterable platinum plasma levels and nephrotoxicityJ Clin Oncol1987523043093806171
   PubMed Web of Science ®Google Scholar
• AranyISafirsteinRLCisplatin nephrotoxicitySemin Nephrol200323546046413680535
   PubMed Web of Science ®Google Scholar
• CavalettiGTrediciGPizziniGMinoiaATissue platinum concentrations and cisplatin schedulesLancet1990336872110031004
   Web of Science ®Google Scholar